In pituitary tumors, E2 treatment promoted ZDHHC7‐ and ZDHHC22‐mediated palmitoylation of ERα at Cys477, enhanced plasma membrane ERα pools, and thus activated ERK1/2, thereby promoting tumor cell proliferation [101, 102, 103] (Fig. 2, Table 1). The gene discussed is MAPK3; the disease is neoplasm.